Total Payments
$2.7M
2024 Payments
$497,831
Companies
49
Transactions
911
Medicare Patients
549
Medicare Billing
$71,358
Payment Breakdown by Category
Consulting$1.8M (66.8%)
Research$738,523 (27.0%)
Other$91,142 (3.3%)
Travel$67,696 (2.5%)
Food & Beverage$9,749 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.8M | 416 | 66.8% |
| Unspecified | $738,523 | 198 | 27.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,158 | 49 | 3.1% |
| Travel and Lodging | $67,696 | 113 | 2.5% |
| Food and Beverage | $9,749 | 132 | 0.4% |
| Honoraria | $4,200 | 1 | 0.2% |
| Grant | $2,784 | 2 | 0.1% |
Payments by Type
General
$2.0M
713 transactions
Research
$738,523
198 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $483,058 | 151 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $365,683 | 44 | $0 (2024) |
| Eli Lilly and Company | $289,883 | 114 | $0 (2024) |
| UCB SA | $219,095 | 31 | $0 (2024) |
| PFIZER INC. | $203,710 | 120 | $0 (2024) |
| Genentech, Inc. | $203,687 | 61 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $130,027 | 17 | $0 (2023) |
| Gilead Sciences, Inc. | $106,403 | 64 | $0 (2024) |
| GlaxoSmithKline, LLC. | $102,764 | 53 | $0 (2024) |
| Insmed, Inc. | $61,540 | 59 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $497,831 | 134 | E.R. Squibb & Sons, L.L.C. ($105,435) |
| 2023 | $364,265 | 125 | AbbVie Inc. ($80,500) |
| 2022 | $298,534 | 86 | ABBVIE INC. ($62,400) |
| 2021 | $367,499 | 93 | AbbVie Inc. ($73,950) |
| 2020 | $482,780 | 112 | E.R. Squibb & Sons, L.L.C. ($94,900) |
| 2019 | $210,962 | 125 | AbbVie, Inc. ($67,414) |
| 2018 | $264,523 | 112 | Eli Lilly and Company ($63,503) |
| 2017 | $248,777 | 124 | PFIZER INC. ($67,722) |
All Payment Transactions
911 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 12/18/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $9,600.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $135.84 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $71.67 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $21.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $20.10 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $13.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/08/2024 | Zambon USA Ltd. | — | Consulting Fee | Cash or cash equivalent | $3,550.00 | General |
| 12/08/2024 | Zambon USA Ltd. | — | Consulting Fee | In-kind items and services | $102.75 | General |
| 12/08/2024 | Zambon USA Ltd. | — | Consulting Fee | In-kind items and services | $31.89 | General |
| 11/26/2024 | Genentech, Inc. | CellCept (Drug), Gazyva | — | Cash or cash equivalent | $2,100.00 | Research |
| Study: Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN • Category: Virology & Specialty Care | ||||||
| 11/25/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 11/15/2024 | Genentech, Inc. | CellCept (Drug), Gazyva | — | Cash or cash equivalent | $4,260.00 | Research |
| Study: Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN • Category: Virology & Specialty Care | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: COVID-19 | ||||||
| 11/09/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $69.40 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $63.14 | General |
| Category: Respiratory | ||||||
| 10/30/2024 | Genentech, Inc. | CellCept (Drug), Gazyva | — | Cash or cash equivalent | $5,362.50 | Research |
| Study: Gazyva in Lupus Nephritis in adolescent patients • Category: Virology & Specialty Care | ||||||
| 10/29/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $10,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/24/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $10,400.00 | General |
| 10/24/2024 | Genentech, Inc. | Gazyva (Biological) | — | Cash or cash equivalent | $5,200.00 | Research |
| Study: Gazyva for the treatment of MN • Category: BioOncology | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 10/21/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | E.R. Squibb & Sons, L.L.C. | $57,000 | 6 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod | E.R. Squibb & Sons, L.L.C. | $45,600 | 1 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | E.R. Squibb & Sons, L.L.C. | $33,600 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Bausch Health US, LLC | $33,000 | 13 |
| Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | Genentech, Inc. | $32,895 | 9 |
| An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 | Regeneron Pharmaceuticals, Inc. | $32,631 | 3 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,440 | 22 |
| A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | Regeneron Pharmaceuticals, Inc. | $24,600 | 2 |
| A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19 | Regeneron Pharmaceuticals, Inc. | $24,600 | 2 |
| Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE | Genentech, Inc. | $23,555 | 7 |
| RANDOMISED DOUBLE BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF OBINUTUZUMAB IN CLASS III AND IV LN | Genentech, Inc. | $21,300 | 8 |
| Gazyva in Lupus Nephritis in adolescent patients | Genentech, Inc. | $21,288 | 6 |
| M14-465 | AbbVie, Inc. | $19,185 | 5 |
| A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 | Regeneron Pharmaceuticals, Inc. | $17,700 | 3 |
| A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 | Regeneron Pharmaceuticals, Inc. | $17,700 | 3 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | E.R. Squibb & Sons, L.L.C. | $16,200 | 1 |
| A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA) | E.R. Squibb & Sons, L.L.C. | $15,300 | 3 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $14,350 | 10 |
| Gazyva for the treatment of MN | Genentech, Inc. | $13,813 | 3 |
| STUDY TO INVESTIGATE SAFETY AND EFFICIACY OF OBINUTUZUMAB IN PATIENTS WITH SLE | Genentech, Inc. | $11,317 | 3 |
| Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjgren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis | E.R. Squibb & Sons, L.L.C. | $10,200 | 4 |
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis | ABBVIE INC. | $9,750 | 2 |
| M16-048 | AbbVie, Inc. | $9,550 | 4 |
| Associations between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, including Corticosteroid Use and Body Mass Index | UCB, Inc. | $9,200 | 2 |
| A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis PsA | E.R. Squibb & Sons, L.L.C. | $7,875 | 1 |
| GAZYVA FOR THE TREATMENT OF MN | Genentech, Inc. | $7,475 | 3 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $7,275 | 1 |
| M16-045 | AbbVie, Inc. | $7,200 | 2 |
| COMB157G2302, COMB157G2301 | Novartis Pharma AG | $6,900 | 1 |
| A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | ABBVIE INC. | $6,825 | 2 |
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis | ABBVIE INC. | $6,600 | 2 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (POETYK-PSO-3) | E.R. Squibb & Sons, L.L.C. | $6,600 | 5 |
| A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | AbbVie Inc. | $6,175 | 2 |
| A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy | EMD Serono, Inc. | $6,000 | 2 |
| Related to multiple studies | EMD Serono, Inc. | $6,000 | 2 |
| A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjgren's Syndrome, or Branebrutinib | E.R. Squibb & Sons, L.L.C. | $5,700 | 1 |
| Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjgren's Syndrome, or Branebrutinib Treatment | E.R. Squibb & Sons, L.L.C. | $5,400 | 1 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | AbbVie Inc. | $5,325 | 1 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | AbbVie Inc. | $4,970 | 1 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | NS Pharma, Inc. | $4,970 | 1 |
| M16-045 | AbbVie Inc. | $4,800 | 1 |
| A Phase IIIb, Multicenter, randomized, parallel-group, open-label study to evaluate the effects of ocrelizumab on immune responses in patients with Relapsing forms of multiple sclerosis | F. Hoffmann-La Roche AG | $4,617 | 1 |
| evaluate Efficacy and Safety of Obinituzumab in Patients with SLE to Obinutuzumab Chine SLE | Genentech, Inc. | $4,260 | 1 |
| GAZYVA IN LUPUS NEPHRITIS IN ADOLESCENT PATIENTS | Genentech, Inc. | $4,063 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis. | Biogen, Inc. | $4,050 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Nave to Biologic Disease-modifying Anti-rheumatic Drugs. | E.R. Squibb & Sons, L.L.C. | $3,575 | 1 |
| M16-006 | AbbVie, Inc. | $3,500 | 1 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (OptIMMize-2) | AbbVie Inc. | $3,195 | 1 |
| Related to Multiple Studies | EMD Serono, Inc. | $3,000 | 1 |
| A PHASE 1B, OPEN-LABEL, SINGLE DOSE STUDY ASSESSING THE PHARMACOKINETICS, SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVENOUS ANTI-SPIKE(S) SARS-COV-2 MONOCLONAL ANTIBODIES (CASIRIVIMAB+IMDEVIMAB) FOR THE TREATMENT OF PEDIATRIC PATIENTS HOSPITALIZED DUE TO COVID-19 | Regeneron Pharmaceuticals, Inc. | $2,600 | 1 |
| A PHASE 2A, OPEN-LABEL STUDY ASSESSING PHARMACOKINETICS, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF SINGLE-DOSE SUBCUTANEOUS OR INTRAMUSCULAR ANTI- SPIKE(S) SARS-COV-2 MONOCLONAL ANTIBODIES (CASIRIVIMAB AND IMDEVIMAB) IN HIGH-RISK PEDIATRIC SUBJECTS UNDER 12 YEARS OF AGE | Regeneron Pharmaceuticals, Inc. | $2,600 | 1 |
| OMS721-GNP-001 | Omeros Corporation | $2,363 | 1 |
| The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases | UCB, Inc. | $2,300 | 1 |
| Tuberculosis and Viral Hepatitis in Patients Treated with Certolizumab Pegol in Asia-Pacific Countries and Worldwide Real-World and Clinical Trial Data | UCB, Inc. | $2,300 | 1 |
| Tuberculosis and Viral Hepatitis in Patients Treated with Certolizumab Pegol in Asia-Pacific Countries and Worldwide: Real-World and Clinical Trial Data | UCB, Inc. | $2,300 | 1 |
| Publication support research related | Novartis Pharma AG | $2,104 | 1 |
| M15-572 | AbbVie, Inc. | $2,000 | 1 |
| An Open-Label, Single-arm, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Japanese Subjects With Moderate-to-Severe Psoriasis | E.R. Squibb & Sons, L.L.C. | $1,500 | 2 |
| M13-542 | AbbVie, Inc. | $1,500 | 1 |
| BODY MASS INDEX AND SYSTEMIC CORTICOSTEROID USE AS INDICATORS OF DISEASE BURDEN AND THEIR INFLUENCE ON THE SAFETY PROFILE OF CERTOLIZUMAB PEGOL ACROSS INDICATIONS | UCB, Inc. | $1,240 | 1 |
| XELJANZ CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS AN ANALYSIS OF POOLED CLINICAL TRIAL DATA | UCB, Inc. | $840.00 | 1 |
| DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA | UCB, Inc. | $840.00 | 1 |
| Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis by Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations? | UCB, Inc. | $840.00 | 1 |
| TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS AN ANALYSIS OF THREE US CLAIMS DATABASES | UCB, Inc. | $820.00 | 1 |
| TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS: AN ANALYSIS OF THREE US CLAIMS DATABASES | UCB, Inc. | $820.00 | 1 |
| M11-327 | AbbVie, Inc. | $500.00 | 1 |
| Annual Diagnostic Prevalence of Ankylosing Spondylitis (AS) in the United States Using Medicare and MarketScan Data | UCB, Inc. | $420.00 | 1 |
| Annual Diagnostic Prevalence of Ankylosing Spondylitis AS in the United States Using Medicare and MarketScan Data | UCB, Inc. | $420.00 | 1 |
| Do TNF Inhibitors Impact the Comorbidities and Extra-Articular Manifestations, and Thereby Alter the Natural History of Ankylosing Spondylitis? | UCB, Inc. | $420.00 | 1 |
| Risk of Tuberculosis and Viral Hepatitis in Patients Treated with Certolizumab Pegol in Asia-Pacific Countries: Results from Post-Marketing Data | UCB, Inc. | $420.00 | 1 |
| Do Anti-TNFs Impact the Comorbidities and Extra-Articular Manifestations, and Thereby Alter the Natural History of Ankylosing Spondylitis? | UCB, Inc. | $400.00 | 1 |
| Risk of Tuberculosis and Viral Hepatitis in Patients Treated with Certolizumab Pegol in Asia-Pacific Countries: Results from Clinical Trials and Post-Marketing Data | UCB, Inc. | $400.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 125 | 207 | $65,636 | $15,608 |
| 2022 | 3 | 124 | 210 | $63,240 | $17,616 |
| 2021 | 4 | 146 | 245 | $64,322 | $20,615 |
| 2020 | 4 | 154 | 250 | $59,243 | $17,518 |
Total Patients
549
Total Services
912
Medicare Billing
$71,358
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 79 | 150 | $41,885 | $10,099 | 24.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 23 | 32 | $13,200 | $2,969 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 25 | $10,551 | $2,540 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 73 | 137 | $35,607 | $9,844 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 38 | 59 | $22,703 | $6,647 | 29.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 13 | 14 | $4,930 | $1,125 | 22.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 73 | 143 | $32,396 | $10,614 | 32.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 21 | 39 | $12,813 | $4,538 | 35.4% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2021 | 40 | 51 | $13,743 | $3,792 | 27.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $5,370 | $1,671 | 31.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 79 | 152 | $30,726 | $8,447 | 27.5% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 42 | 63 | $16,884 | $5,809 | 34.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 22 | 24 | $6,912 | $2,011 | 29.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 11 | 11 | $4,721 | $1,252 | 26.5% |
About Dr. Kevin Winthrop, MD
Dr. Kevin Winthrop, MD is a Infectious Disease healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679509525.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Winthrop, MD has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $497,831 received in 2024. These payments were reported across 911 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($1.8M).
As a Medicare-enrolled provider, Winthrop has provided services to 549 Medicare beneficiaries, totaling 912 services with total Medicare billing of $71,358. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Portland, OR
- Active Since 06/23/2006
- Last Updated 01/16/2013
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1679509525
Products in Payments
- XELJANZ (Drug) $178,911
- Sotyktu (Drug) $111,825
- RINVOQ (Biological) $104,884
- CellCept (Drug) $75,945
- GAZYVA (Biological) $68,754
- KEVZARA (Biological) $63,749
- Cimzia (Drug) $54,560
- Gazyva (Biological) $41,628
- Arikayce (Drug) $39,731
- SKYRIZI (Biological) $36,075
- XIFAXAN (Drug) $33,000
- Humira (Biological) $30,713
- ORENCIA (Biological) $30,113
- Palynziq (Drug) $28,463
- Cipro (Drug) $26,456
- SOTYKTU (Drug) $25,775
- SHINGRIX (Biological) $24,876
- NUZYRA (Drug) $20,608
- OCREVUS (Biological) $19,252
- TREMFYA (Drug) $16,850
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Portland
Wendi Drummond, D.o, D.O
Infectious Disease — Payments: $127,524
Infectious Disease $127,524
Mr. David Gilbert, Md, MD
Infectious Disease — Payments: $27,605
Infectious Disease $27,605
Kieren Marr
Infectious Disease — Payments: $18,569
Infectious Disease $18,569
Paul Sehdev, Md, MD
Infectious Disease — Payments: $13,123
Infectious Disease $13,123
Dr. Phil Alday, Md, Phd, MD, PHD
Infectious Disease — Payments: $8,943
Infectious Disease $8,943
Sunwen Chou, Md, MD
Infectious Disease — Payments: $1,817
Infectious Disease $1,817